Straits Times Index
3,332.80 -10.55 (-0.32%) Nikkei
39,583.08 +241.54 (+0.61%) Hang Seng
17,718.61 +2.14 (+0.01%) FTSE 100
8,164.12 -15.56 (-0.19%) Bitcoin USD
60,224.18 -1,228.66 (-2.00%) CMC Crypto 200
1,282.52 -1.31 (-0.10%)
BIIB Jun 2024 227.500 put
| Previous close | 1.1500 |
| Open | 1.1500 |
| Bid | 0.0000 |
| Ask | 3.1000 |
| Strike | 227.50 |
| Expiry date | 2024-06-28 |
| Day's range | 1.1500 - 1.1500 |
| Contract range | N/A |
| Volume | |
| Open interest | 13 |
ReutersEisai and Biogen launch Alzheimer's drug Leqembi in China
Leqembi, which works by removing a toxic protein called beta amyloid from the brain, is the first Alzheimer's treatment proven to alter the course of the fatal, brain-wasting disease. Eisai has also collaborated with a major Chinese medical insurance firm to plan partial coverage of the drug cost, the companies said without naming the insurer. China approved the treatment in January after a standard approval from the U.S. Food and Drug Administration last July.
GlobeNewswire“LEQEMBI®” (Lecanemab) for the Treatment of Alzheimer’s Disease Launched in China
China is the Third Country to Launch LEQEMBI Following the United States and JapanTOKYO and CAMBRIDGE, Mass., June 27, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody “LEQEMBI®” (brand name in China: “乐意保®”, generic name: lecanemab) has b
ZacksFDA Accepts Ionis' (IONS) NDA for Rare Disease Drug Olezarsen
The FDA grants priority review to Ionis' (IONS) filing seeking approval for olezarsen to treat adults with familial chylomicronemia syndrome. A final decision is expected in December 2024.
